NEW YORK ( TheStreet) -- CHANGE IN RATINGSActuant ( ATU) downgraded at Citigroup to Neutral from Buy, Citigroup said. $29 price target. More balanced risk/reward outlook. Broadcom ( BRCM) rated new Buy at Cantor. $40 price target. Infrastructure business trends remain strong and the NetLogic purchase should boost growth. Dolby ( DLB) rated new Sell at Goldman. $39 price target. Company faces multiple growth headwinds. Ford Motor ( F) rated new Hold at Stifel. Company had been losing market share but is now better positioned for the next major product cycle. First Niagara ( FNFG) upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $9 price target. Stock appears oversold and sports a 4% dividend yield. Gartner ( IT) rated new Market Perform at Wells. IT was initiated with a Market Perform rating, Wells Fargo said. Company is leveraged to near-term IT spending concerns. LKQ ( LKQ) downgraded at Baird from Outperform to Neutral, Robert Baird said. Valuation call, based on a $37 price target. McGraw-Hill ( MHP) upgraded at Benchmark from Hold to Buy, Benchmark said. $53 price target. Company has strong growth prospects in finance and can unlock value by separating the education business. Microsemi ( MSCC) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Valuation call, following the recent pullback. Qualcomm ( QCOM) rated new Buy at Cantor Fitzgerald. $66 price target. Long-term trends remain positive for wireless devices. Riverbed ( RVBD) rated new Strong Buy at Needham. $25 price target. Stock looks oversold at current levels. Spectra Energy ( SE) upgraded at UBS to Buy from Neutral, UBS said. $31 price target. Prices already reflect NGL weakness. Veeco Instruments ( VECO) rated new Equal-weight at Piper. Overall market outlook remains uncertain. Western Gas Partners ( WES) upgraded at UBS to Buy from Neutral, UBS said. $48 price target. Continue to expect strong distribution growth. Xylem ( XYL) downgraded at Goldman to Sell, Goldman Sachs said. $24 price target. Company is leveraged to softer European and municipal water markets.
STOCK COMMENTS / EPS CHANGES
Arena Pharmaceuticals ( ARNA) numbers increased at BMO. ARNA estimates were raised through 2013, BMO Capital said. Company received better labeling in its FDA approval. Market Perform rating and new $12 price target. Arena Pharmaceuticals target raised at Jefferies. Shares of ARNA now seen reaching $20, Jefferies said. FDA approves Lorcaserin. Buy rating.